

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page # based on the file name "Main Document – clean copy"
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	2
Objectives	3	State specific objectives, including any prespecified hypotheses	2 (Final paragraph)
Methods			
Study design	4	Present key elements of study design early in the paper	1, and line 8 of page 3
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	<ul style="list-style-type: none"> Reported on the topic of study design and participants, line 9-28 of page 3 For data collection, page 5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	Line 15-28, page 3
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Covering all the topic of Measure, page 3-4
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 3 – 4

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

Section/Topic	Item #	Recommendation	Reported on page # based on the file name "Main Document – clean copy"
Bias	9	Describe any efforts to address potential sources of bias	Page 4-7, on the first four lines
Study size	10	Explain how the study size was arrived at	Page 3, line 9-14
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 3-4
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page 5
		(b) Describe any methods used to examine subgroups and interactions	Page 5
		(c) Explain how missing data were addressed	-
		(d) If applicable, describe analytical methods taking account of sampling strategy	Page 5
		(e) Describe any sensitivity analyses	Page 5
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 5, topic of sample characteristic
		(b) Give reasons for non-participation at each stage	Page 5
		(c) Consider use of a flow diagram	-
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 5, line 29-35
		(b) Indicate number of participants with missing data for each variable of interest	-
Outcome data	15*	Report numbers of outcome events or summary measures	Page 6, on the topic of current tobacco smoking
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page 6-9
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

Section/Topic	Item #	Recommendation	Reported on page # based on the file name "Main Document – clean copy"
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	-
Discussion			
Key results	18	Summarise key results with reference to study objectives	Page 9, on the first three line of the Discussion section
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 11, line 15-22
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 9-11
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 11, line 15-17
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Added on the file name "information relating to article"

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.